Progresivní myopie: Současné trendy v diagnostice, léčbě a výzkumu

Říj 16, 2025 | QR kódy

Reference:

  1. Holden BA, Fricke TR, Wilson DA et al. Global Prevalence of Myopia and High Myopia and Temporal Trends from 2000 through 2050. Ophthalmology 2016;123(5),1036–1042.
  2. Saw SM, Gazzard G, Shih-Yen EC et al. Myopia and Associated Pathologic Complications. Ophthalmic and Physiological Optics 2005; 25(5), 381–391.
  3. Cai XB, Shen SR, Chen DF, Zhang Q, Jin ZB. An overview of myopia genetics. Exp Eye Res. 2019 Nov;188:107778.
  4. Lee MW, Lee SE, Lim HB, Kim JY. Longitudinal changes in axial length in high myopia: a 4-year prospective study. Br J Ophthalmol. 2020 May;104(5):600-603.
  5. Tideman JW, Snabel MC, Tedja MS et al. Association of Axial Length With Risk of Uncorrectable Visual Impairment for Europeans With Myopia. JAMA Ophthalmol. 2016 Dec 1;134(12):1355-1363.
  6. Flitcroft DI. The complex interactions of retinal, optical and environmental factors in myopia aetiology. Prog Retin Eye Res. 2012 Nov;31(6):622-60.
  7. Xiong S, Sankaridurg P, Naduvilath T et al. Time spent in outdoor activities in relation to myopia prevention and control: a meta-analysis and systematic review. Acta Ophthalmol. 2017 Sep;95(6):551-566.
  8. Zhou X, Pardue MT, Iuvone PM et al. Dopamine signaling and myopia development: What are the key challenges. Prog Retin Eye Res. 2017 Nov;61:60-71.
  9. Du Y, Meng J, He W et al. Complications of high myopia: An update from clinical manifestations to underlying mechanisms. Adv Ophthalmol Pract Res. 2024 Jun 21;4(3):156-163.
  10. Bullimore MA, Johnson LA. Overnight orthokeratology. Cont Lens Anterior Eye. 2020 Aug;43(4):322-332.
  11. Chamberlain P, Peixoto-de-Matos SC, Logan NS et al. A 3-year Randomized Clinical Trial of MiSight Lenses for Myopia Control. Optom Vis Sci. 2019 Aug;96(8):556-567.
  12. Lam CSY, Tang WC, Tse DY et al. Defocus Incorporated Multiple Segments (DIMS) spectacle lenses slow myopia progression: a 2-year randomised clinical trial. Br J Ophthalmol. 2020 Mar;104(3):363-368.
  13. Chia A, Chua WH, Cheung YB et al. Atropine for the treatment of childhood myopia: safety and efficacy of 0.5%, 0.1%, and 0.01% doses (Atropine for the Treatment of Myopia 2). Ophthalmology. 2012 Feb;119(2):347-54.
  14. Chen J, Tang Y, Lin Z et al. Effect and safety posterior scleral reinforcement on controlling myopia in children: a meta-analysis. Int Ophthalmol. 2024 Feb 6;44(1):8.